New trial
Phase 1/2 ETX-636 pan-mutant-selective PI3Kα inhibitor trial
- Trial ID
- NCT06993844 on ClinicalTrials.gov
- Cancer type
- Other Solid Tumors
- Stage of research
- First-in-human
- Published in
- New in Oncology - July 3, 2025
This open-label study evaluates ETX-636 as monotherapy in advanced solid tumors with PIK3CA mutations and in combination with fulvestrant in HR+/HER2- metastatic breast cancer. Conducted by Ensem Therapeutics in Fairfax, it investigates safety, tolerability, pharmacokinetics, and preliminary efficacy in a first-in-human setting.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings